Judge Sleet of the U.S. District Court for the District of Delaware has dismissed Genentech’s complaint against Amgen for allegedly failing to comply with the the Biologics Price Competition and Innovation Act (BPCIA), but...more
3/10/2017
/ aBLA ,
Amgen ,
Biosimilars ,
BPCIA ,
Dismissals ,
Genentech ,
Information Sharing ,
Patent Dance ,
Patent Infringement ,
Patents ,
Pharmaceutical Patents ,
Subject Matter Jurisdiction
In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has filed a complaint against Amgen, Inc., alleging that after opting into the...more
2/24/2017
/ aBLA ,
Biologics ,
Biosimilars ,
BPCIA ,
Confidential Information ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Injunctive Relief ,
Motion to Compel ,
Patent Dance ,
Patent Infringement ,
Pharmaceutical Patents